Kelly L Stratton, MD
Disclosures: Honoraria-Bayer Corporation-Consultant - Payment made to the Department of Urology|Honoraria-Bayer Corporation-Advisory Board - Payment made to the Department of Urology|Consulting Fee-AMRO Pharma-Advisory Board - Payment made to the Department of Urology|Honoraria-Sun Pharma-Webinar - Payment made to the Department of Urology|Consulting Fee-Mryiad Genetics-Consulting Agreement - Payment made to the Department of Urology|Professional Service Fee-Ebix/Oakstone Review-Honoraria - Payment made to the Department of Urology

Kelly Stratton, M.D., is an Assistant Professor of Urologic Oncology and Adjunct Assistant Professor of Medical Oncology at the University of Oklahoma, Stephenson Cancer Center.  He serves as the Disease Site Chair for Urologic Cancers and as a member of the Oklahoma TSET Phase I Clinical Trials Program.  He completed his urology training at Vanderbilt University Medical Center and fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center.  His interests include clinical trial development and the treatment of localized and advanced cancers with immunotherapeutic agents.  He also has a focus in prostate cancer imaging, MRI/US Fusion Biopsy, and focal treatment of localized prostate cancer.